Core Viewpoint - The company, Liaoning Chengda Biological Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 to discuss adjustments to its fundraising projects and internal investment structure, including the termination of certain research projects and the allocation of funds to new initiatives [1][18]. Meeting Details - The second extraordinary general meeting of shareholders will be held on December 23, 2025, at 9:30 AM in Shenyang, Liaoning Province [4]. - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [2][6]. Fundraising Project Adjustments - The company plans to optimize the internal investment structure of its "Human Vaccine Research Project" by terminating five research sub-projects and reallocating unused funds to other ongoing and new sub-projects, specifically the "High-Value Pneumococcal Polysaccharide Conjugate Vaccine" and "High-Dose Influenza Virus Split Vaccine" [19][30]. - A total of 100 million yuan will be specifically allocated to increase capital in its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., to support the implementation of the "High-Dose Influenza Virus Split Vaccine" [19][43]. Project Timeline Extensions - The fundraising usage period for the "Human Vaccine Research Project" and "Biotechnology Product R&D Production Base Project" has been extended to December 2028 to adapt to global macroeconomic changes and industry trends [20][46]. - The adjustments made will not affect the total planned investment amount for the "Human Vaccine Research Project" [41]. Financial Management and Compliance - The company has established a special account for the management of the raised funds, ensuring that all funds are used specifically for the designated projects [45]. - The adjustments and extensions have been approved by the company's board and will be submitted for shareholder approval at the upcoming meeting [25][46].